Table 2 Clinical and therapeutic characteristics
Variables | Total number of patients (n = 61) | Cannabis users (n = 9) | Cannabis non-users (n = 52) | p |
|---|---|---|---|---|
Psychiatric diagnosis | ||||
Schizophrenia | 20 (32.9%) | 5 (55.5%) | 15 (28.8%) | |
Schizophreniform disorder | 26 (42.6%) | 1 (11.1%) | 25 (48.1%) | |
Brief psychotic disorder | 10 (16.4%) | 1 (11.1%) | 9 (17.2%) | 0.10 |
Cannabis-induced psychosis | 3 (4.9%) | 2 (22.2%) | 1 (1.9%) | |
Delusional psychosis | 1 (1.6%) | 0 (0%) | 1 (1.9%) | |
Psychotic disorder not otherwise specified | 1 (1.6%) | 0 (0%) | 1 (1.9%) | |
PANSS total score | 99.5 ± 20.6 | 101.6 ± 20.5 | 99.1 ± 20.8 | 0.65 |
PANSS positive score | 25.1 ± 6 | 27 ± 6.3 | 24.8 ± 6 | 0.43 |
PANSS negative score | 24.3 ± 9.3 | 25.7 ± 9.8 | 24 ± 9.3 | 0.56 |
GAF score | 32.4 ± 8 | 30 ± 5.6 | 33.5 ± 8.3 | 0.28 |
Duration of untreated psychosis (weeks) | 39.6 ± 63.7 | 28.6 ± 35.2 | 41.5 ± 87.4 | 0.45 |
Antipsychotic treatment | ||||
First-generationantipsychotic | 25(41%) | 4 (44.4%) | 21 (40.4%) | |
Second-generationantipsychotic | 19 (31.1%) | 2 (22.2%) | 17 (32.7%) | 0.84 |
Co-treatment of first- and second-generation antipsychotics | 17 (27.8%) | 3 (33.3%) | 14 (26.9%) | |
Chlorpromazine equivalent | 619.8 ± 419.8 mg | 914.0 ± 629.8 mg | 568.8 ± 356.6 mg | 0.16 |
Simpson Angus scale score | 3.8 ± 3.2 | 4.3 ± 2.6 | 3.7 ± 3. | 0.37 |
Duration of hospitalization (days) | 29.1 ± 16.6 | 43.3 ± 15.5 | 26.7 ± 15.6 | 0.005 |